Selected Publications

Mayer M, Seewald N, Babcock A, Homet Moreno B, Ramamurthy C, Li H, Mamtani R.: Untreated advanced urothelial carcinoma (aUC) in the modern treatment era: Patterns of care from a decade-long national cohort. 2026 American Society of Clinical Oncology Annual Meeting, Chicago IL. J Clin Oncol, 44, Jun 2026 Notes: "Poster Presentation"

Subramanian P, Shyamsunder S, Eshaghi K, Mamtani R, Litt HK.: Gaps in patient-facing information on artificial intelligence in cancer care: A cross-sectional analysis. 2026 American Society of Clinical Oncology Annual Meeting, Chicago IL. J Clin Oncol, 44, Jun 2026 Notes: "Oral Presentation"

Chow RD, Rothen J, Long JB, Soulos PR, Wang X, Mamtani R, Ma S, Kunst N, Dinan MA, Gross CP.: Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer. JAMA Netw Open 9: e2614919, May 2026.

Martei YM, Chen K, Obasohan M, Mamtani R, Aakhus E, Shulman LN, Hubbard RA, Clark A.: Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer. JNCI Cancer Spectr Apr 2026.

Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Narayan V, Mei L, Takvorian S, Haas NB, Parikh RB, Mistry R, Mamtani R.: OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care. Oncologist Apr 2026.

Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.: Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. Stat Med 45, Apr 2026.

Litt H, Mehta P, Sahni A, Mamtani R.: FDA-authorized oncology artificial intelligence and machine learning devices and their clinical evidence: A cross-sectional analysis. J Cancer Policy 48: 100743, Apr 2026.

Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y.: Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Proc Natl Acad Sci U S A 123: e2533449123, Feb 2026.

Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R.: Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis. Clin Genitourin Cancer Feb 2026.

Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA.: A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. J Natl Compr Canc Netw 24: e257131, Feb 2026.